My earlier link didn't work. Check out this 3 mo comparison in performance for SCLN, REGN, DSCO, CEGE and DNDN. Also go back 6 mo to see how their performance played out over that time frame. DNDN and CEGE are underperforming the others from their March-April lows. Seems to indicate that market doesn't have as much confidence in their trials and/or therapeutic and vaccine approach to cancers. Time will tell whether the market has misjudged DNDN. All I can say is that DNDN is building a very strong base in the $5-6 dollar range. My bets have been placed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.